Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated
